These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7405674)

  • 1. Haloperidol plasma level monitoring in psychiatric patients.
    Morselli PL; Zarifian E; Cuche H; Bianchetti G; Cotterau MJ; Deniker P
    Adv Biochem Psychopharmacol; 1980; 24():529-36. PubMed ID: 7405674
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
    LLerena A; de la Rubia A; Berecz R; Dorado P
    Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol; a useful psychiatric drug.
    Iveson-Iveson J
    Nurs Mirror Midwives J; 1976 Nov; 143(20):77. PubMed ID: 1049981
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of smoking and cytochrome P450 2D6*10 allele on the plasma haloperidol concentration/dose ratio.
    Ohara K; Tanabu S; Yoshida K; Ishibashi K; Ikemoto K; Shibuya H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Sep; 27(6):945-9. PubMed ID: 14499311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of route of administration on haloperidol plasma levels in psychotic patients.
    Bianchetti G; Zarifian E; Poirier-Littre MF; Morselli PL; Deniker P
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):324-7. PubMed ID: 7429678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haloperidol plasma level monitoring in neuropsychiatric patients.
    Morselli PL; Bianchetti G; Dugas M
    Ther Drug Monit; 1982; 4(1):51-8. PubMed ID: 7041338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of carbamazepine on neuroleptic plasma levels and efficacy.
    Fast DK; Jones BD; Kusalic M; Erickson M
    Am J Psychiatry; 1986 Jan; 143(1):117-8. PubMed ID: 3942266
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduced haloperidol/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients.
    Someya T; Takahashi S; Shibasaki M; Inaba T; Cheung SW; Tang SW
    Psychiatry Res; 1990 Feb; 31(2):111-20. PubMed ID: 2326392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual variability in response to haloperidol.
    Forsman AO
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):9-12. PubMed ID: 1019146
    [No Abstract]   [Full Text] [Related]  

  • 10. [Results of use of haloperidol in a medicopedagogical institution].
    Renard P; Bicheron C; Morin Y
    Rev Neuropsychiatr Infant; 1965 Aug; 13(8):587-97. PubMed ID: 5850632
    [No Abstract]   [Full Text] [Related]  

  • 11. Monitoring of haloperidol serum levels and it's clinical significance.
    Itoh H; Yagi G; Tateyama M; Fujii Y; Iwamura K; Ichikawa K
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(1):51-62. PubMed ID: 6539490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies with haloperidol in the pedopsychiatric institutional practice].
    Jacobs R
    Prax Kinderpsychol Kinderpsychiatr; 1966; 15(2):67-70. PubMed ID: 5928744
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio.
    Ohara K; Tanabu S; Ishibashi K; Ikemoto K; Yoshida K; Shibuya H
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):347-50. PubMed ID: 12691769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical experiences with haloperidol in mental patients].
    Angyal L
    Orv Hetil; 1968 Jan; 109(3):136-40. PubMed ID: 5669638
    [No Abstract]   [Full Text] [Related]  

  • 15. [C-reactive protein content of the cerebrospinal fluid and blood serum in mental disorders].
    Krasil'nikova MN; Alisevich KD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1970; 70(11):1678-81. PubMed ID: 5509924
    [No Abstract]   [Full Text] [Related]  

  • 16. [Haloperidol Polfa in the treatment of mental disorders].
    Bogdanowicz E; Bojdecki K; Gawrońska I; Jakimow B; Paterska L; Puzyński S; Wasilewski B
    Psychiatr Pol; 1975; 9(6):656-7. PubMed ID: 1197498
    [No Abstract]   [Full Text] [Related]  

  • 17. [Haloperidol in mental patient treatment].
    Berthiaume M; Baser T; Desrochers J; Feldman N; Hamel O; Hoc J; Moamai N
    Union Med Can; 1966 Feb; 95(2):195-7. PubMed ID: 5905194
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of clinical literature on haloperidol.
    Crane GE
    Int J Neuropsychiatry; 1967 Aug; 3():Suppl 1:110-27. PubMed ID: 4860978
    [No Abstract]   [Full Text] [Related]  

  • 19. [Evaluation of the effectiveness of treatment with haloperidol].
    Belciugăţeanu C; Botez E; Sîrbu AM; Ellenbogen S
    Neurol Psihiatr Neurochir; 1967; 12(3):265-71. PubMed ID: 5594662
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.